Aimed Bio Inc. (KOSDAQ:0009K0)
South Korea · Delayed Price · Currency is KRW
56,300
-4,200 (-6.94%)
At close: Mar 19, 2026
Revenue by Segment
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
|---|
Researches, Develops, Produces, and Sells Antibody-Based Therapeutics | 11.76B | 171.21M | 111.09M |
Researches, Develops, Produces, and Sells Antibody-Based Therapeutics Growth | 6768.70% | 54.11% | - |
| 11.76B | 171.21M | 111.09M |
| 6768.70% | 54.11% | - |
Revenue by Geography
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
| FY 2024 | FY 2023 | FY 2022 |
|---|
| Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
|---|
| 467.78M | 171.21M | 111.09M |
| 173.21% | 54.12% | - |
| 11.29B | - | - |
| 11.76B | 171.21M | 111.09M |
| 6768.70% | 54.12% | - |
Source: S&P Global Market Intelligence.
